IL-2 therapy in type 1 diabetes: "Trials" and tribulations

Clinical Immunology

Volumn 149, Issue 3, 2013, Pages 324-331

  Long, S Alice ^a   Buckner, Jane H ^a   Greenbaum, Carla J ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

Clinical trials; ; GVHD; ; HCV induced vasculitis; IL 2; ; Regulatory T cells; ; Type 1 diabetes;

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; RAPAMYCIN;

AGE; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; DRUG MEGADOSE; EOSINOPHILIA; FATIGUE; FLU LIKE SYNDROME; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOTHERAPY; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY CARCINOMA; LOW DRUG DOSE; MELANOMA; MYALGIA; NATURAL KILLER CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; VASCULITIS;

CLINICAL TRIALS;; EFFECTOR T CELLS; GRAFT VERSUS HOST DISEASES; GVHD; GVHD;; HCV-INDUCED VASCULITIS; IL-2 RECEPTOR; IL-2;; IL2R; MIXED MEAL TOLERANCE TEST; MMTT; REGULATORY T CELLS; REGULATORY T CELLS;; T1D; TEFF; TREG; TYPE 1 DIABETES; TYPE 1 DIABETES;;

ANIMALS; AUTOIMMUNITY; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNE TOLERANCE; INTERLEUKIN-2; MICE; RECEPTORS, INTERLEUKIN-2; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 84887024554     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.02.005     Document Type: Review

References (57)

1. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. May 30 2002, 346(22):1692-1698.
2. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. Jun 23 2005, 352(25):2598-2608.
3. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. Nov 26 2009, 361(22):2143-2152.
4. Orban T., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet Jul 30 2011, 378(9789):412-419.
5. Malek T.R. The biology of interleukin-2. Annu. Rev. Immunol. 2008, 26:453-479.
6. Buckner J.H. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat. Rev. Immunol. Dec 2010, 10(12):849-859.
7. + T cells. Eur. J. Immunol. Nov 1995, 25(11):3053-3059.
8. Suzuki H., Kundig T.M., Furlonger C., Wakeham A., Timms E., Matsuyama T., et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science Jun 9 1995, 268(5216):1472-1476.
9. Willerford D.M., Chen J., Ferry J.A., Davidson L., Ma A., Alt F.W. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity Oct 1995, 3(4):521-530.
10. Aoki C.A., Roifman C.M., Lian Z.X., Bowlus C.L., Norman G.L., Shoenfeld Y., et al. IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J. Autoimmun. Aug 2006, 27(1):50-53.
11. Strieder T.G., Drexhage H.A., Lam-Tse W.K., Prummel M.F., Tijssen J.G., Wiersinga W.M. A reduced IL2R (CD25) expression level in first and second degree female relatives of autoimmune thyroid disease patients. A sign of a poor capability to preserve tolerance?. Autoimmunity Mar 2006, 39(2):93-98.
12. + CD25(high) T cells in human STAT5b deficiency. J. Immunol. Sep 1 2006, 177(5):2770-2774.
13. + regulatory T cells. J. Immunol. Jan 1 2007, 178(1):280-290.
14. Fontenot J.D., Rasmussen J.P., Gavin M.A., Rudensky A.Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. Nov 2005, 6(11):1142-1151.
15. +. J. Immunol. Feb 15 2007, 178(4):2018-2027.
16. +. Int. Immunol. Mar 2008, 20(3):421-431.
17. Brusko T.M., Wasserfall C.H., Hulme M.A., Cabrera R., Schatz D., Atkinson M.A. Influence of membrane CD25 stability on T lymphocyte activity: implications for immunoregulation. PLoS One 2009, 4(11):e7980.
18. Park M.J., Shin J.S., Kim Y.H., Hong S.H., Yang S.H., Shin J.Y., et al. Murine mesenchymal stem cells suppress T lymphocyte activation through IL-2 receptor alpha (CD25) cleavage by producing matrix metalloproteinases. Stem Cell Rev. Jun 2011, 7(2):381-393.
19. Schulz O., Sewell H.F., Shakib F. Proteolytic cleavage of CD25, the alpha subunit of the human T cell interleukin 2 receptor, by Der p 1, a major mite allergen with cysteine protease activity. J. Exp. Med. Jan 19 1998, 187(2):271-275.
20. Dendrou C.A., Wicker L.S. The IL-2/CD25 pathway determines susceptibility to T1D in humans and NOD mice. J. Clin. Immunol. Sep 9 2008, 6:685-696.
21. + regulatory T cell function in situ and resistance to autoimmune diabetes in NOD mice. J. Immunol. Nov 1 2008, 181(9):6283-6292.
22. Tang Q., Adams J.Y., Penaranda C., Melli K., Piaggio E., Sgouroudis E., et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity May 2008, 28(5):687-697.
23. Yamanouchi J., Rainbow D., Serra P., Howlett S., Hunter K., Garner V.E., et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat. Genet. Mar 2007, 39(3):329-337.
24. Grinberg-Bleyer Y., Baeyens A., You S., Elhage R., Fourcade G., Gregoire S., et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J. Exp. Med. Aug 30 2010, 207(9):1871-1878.
25. Koulmanda M., Budo E., Bonner-Weir S., Qipo A., Putheti P., Degauque N., et al. Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc. Natl. Acad. Sci. U. S. A. Aug 7 2007, 104(32):13074-13079.
26. Rabinovitch A., Suarez-Pinzon W.L., Shapiro A.M., Rajotte R.V., Power R. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes Mar 2002, 51(3):638-645.
27. Bacchetta R., Passerini L., Gambineri E., Dai M., Allan S.E., Perroni L., et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J. Clin. Invest. Jun 2006, 116(6):1713-1722.
28. Ochs H.D., Gambineri E., Torgerson T.R. IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol. Res. 2007, 38(1-3):112-121.
29. Wildin R.S., Ramsdell F., Peake J., Faravelli F., Casanova J.L., Buist N., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. Jan 2001, 27(1):18-20.
30. + T regulatory cells in human autoimmunity: more than a numbers game. J. Immunol. Sep 1 2011, 187(5):2061-2066.
31. + T-cells in type 1 diabetes. Diabetes May 2005, 54(5):1407-1414.
32. Lindley S., Dayan C.M., Bishop A., Roep B.O., Peakman M., Tree T.I. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes Jan 2005, 54(1):92-99.
33. +CD25high regulatory T cells in human autoimmune diabetes. J. Autoimmun. Feb 2005, 24(1):55-62.
34. + regulatory T cells. J. Immunol. Nov 15 2008, 181(10):7350-7355.
35. + T cells in human type 1 diabetes: report of the Immunology of Diabetes Society T Cell Workshop. Ann. N. Y. Acad. Sci. Oct 2006, 1079:9-18.
36. + regulatory T cell function. J. Immunol. May 1 2012, 188(9):4644-4653.
37. + CD25(high) T cells in type 1 diabetes may be partially mediated by IL-2 deprivation. PLoS One 2009, 4(8):e6527.
38. + regulatory T cells of type 1 diabetic subjects. Diabetes Feb 2010, 59(2):407-415.
39. Marwaha A.K., Crome S.Q., Panagiotopoulos C., Berg K.B., Qin H., Ouyang Q., et al. Cutting edge: increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J. Immunol. Oct 1 2010, 185(7):3814-3818.
40. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature Jun 7 2007, 447(7145):661-678.
41. Hakonarson H., Qu H.Q., Bradfield J.P., Marchand L., Kim C.E., Glessner J.T., et al. A novel susceptibility locus for type 1 diabetes on Chr12q13 identified by a genome-wide association study. Diabetes Apr 2008, 57(4):1143-1146.
42. Todd J.A., Walker N.M., Cooper J.D., Smyth D.J., Downes K., Plagnol V., et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat. Genet. Jul 2007, 39(7):857-864.
43. Lowe C.E., Cooper J.D., Brusko T., Walker N.M., Smyth D.J., Bailey R., et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat. Genet. Aug 5 2007, 9:1074-1082.
44. Long S.A., Cerosaletti K., Wan J.Y., Ho J.C., Tatum M., Wei S., et al. An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4(+) T cells. Genes Immun. Mar 2011, 12(2):116-125.
45. Lotze M.T., Chang A.E., Seipp C.A., Simpson C., Vetto J.T., Rosenberg S.A. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA Dec 12 1986, 256(22):3117-3124.
46. Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., Ettinghausen S.E., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. Dec 5 1985, 313(23):1485-1492.
47. Koreth J., Matsuoka K., Kim H.T., McDonough S.M., Bindra B., Alyea E.P., et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. Dec 1 2011, 365(22):2055-2066.
48. Saadoun D., Rosenzwajg M., Joly F., Six A., Carrat F., Thibault V., et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. Dec 1 2011, 365(22):2067-2077.
49. Long S.A., Rieck M., Sanda S., Bollyky J.B., Samuels P.L., Goland R., et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes Sep 2012, 61(9):2340-2348.
50. Landau D.A., Rosenzwajg M., Saadoun D., Trebeden-Negre H., Klatzmann D., Cacoub P. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis. Arthritis Rheum. Sep 2008, 58(9):2897-2907.
51. Yang J.C., Sherry R.M., Steinberg S.M., Topalian S.L., Schwartzentruber D.J., Hwu P., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. Aug 15 2003, 21(16):3127-3132.
52. Margolin K., Atkins M., Sparano J., Sosman J., Weiss G., Lotze M., et al. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma. Clin. Cancer Res. Apr 1997, 3(4):565-572.
53. McDermott D.F., Trehu E.G., Mier J.W., Sorce D., Rand W., Ronayne L., et al. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor. Clin. Cancer Res. May 1998, 4(5):1203-1213.
54. Trehu E.G., Mier J.W., Dubois J.S., Sorce D., Klempner M.S., Epstein M., et al. Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera. Clin. Cancer Res. Aug 1996, 2(8):1341-1351.
55. Phan G.Q., Attia P., Steinberg S.M., White D.E., Rosenberg S.A. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. Aug 1 2001, 19(15):3477-3482.
56. Atkins M.B., Mier J.W., Parkinson D.R., Gould J.A., Berkman E.M., Kaplan M.M. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N. Engl. J. Med. Jun 16 1988, 318(24):1557-1563.
57. Hulme M.A., Wasserfall C.H., Atkinson M.A., Brusko T.M. Central role for interleukin-2 in type 1 diabetes. Diabetes Jan 2012, 61(1):14-22.